Director Wigzell sells 10,500 SRPT shares at $124.84 (−31.5% of holdings); prior 4 SRPT sales all showed negative 90d returns.
Wigzell Hans Lennart Rudolf, a director of Sarepta Therapeutics, sold 10,500 shares (−31.5% of prior holdings) on 2024-12-12 at $124.84 per share for $1,310,820.00. His prior trading history at this ticker is notably consistent: all 4 prior sales at SRPT occurred on 2024-03-08 and 2023-08-04, and each showed negative 90-day returns (−5.2%, −4.6%, −4.0%, and −27.1% respectively), indicating a pattern of well-timed exits before declines. This sale occurs when SRPT is −22.6% from its 52-week high, though the stock has risen +21.3% over the past 30 days. The company's recent financial profile shows $467,172,000.00 in quarterly revenue with annual revenue growth of +33.3%, but the company was unprofitable over its most recent full fiscal year, and the P/E of 99.05 reflects elevated growth expectations. The director's reduction of his stake by roughly one-third, combined with a track record of well-timed exits at this ticker specifically, merits attention given the company's valuation profile and profitability status.